1. Qin SY, Zhang AQ, Cheng SX, Rong L and Zhang XZ: Drug self-delivery systems for cancer therapy. Biomaterials 112: 234-247, 2017. 

2. Sun NF, Liu ZA, Huang WB, Tian AL and Hu SY: The research of nanoparticles as gene vector for tumor gene therapy. Crit Rev Oncol Hematol 89: 352-357, 2014. 

3. van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, et al: Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracy cline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast 29: 153-159, 2016. 

4. Vago R, Collico V, Zuppone S, Prosperi D and Colombo M: Nanoparticle-mediated delivery of suicide genes in cancer therapy. Pharmacol Res 111: 619-641, 2016. 

5. Banerjee SM, MacRobert AJ, Mosse CA, Periera B, Bown SG and Keshtgar MR: Photodynamic therapy: Inception to applica tion in breast cancer. Breast 31: 105-113, 2017. 

6. Sanchez-Dominguez CN, Gallardo-Blanco HL, RodriguezRodriguez AA, Vela-Gonzalez AV and Sanchez-Dominguez M: Nanoparticles vs cancer: A multifuncional tool. Curr Top Med Chem 14: 664-675, 2014. 

7. Yu M, Wu J, Shi J and Farokhzad OC: Nanotechnology for protein delivery: Overview and perspectives. J Control Release 240: 24-37, 2016. 

8. Beik J, Abed Z, Ghoreishi FS, Hosseini-Nami S, Mehrzadi S, Shakeri-Zadeh A and Kamrava SK: Nanotechnology in hyperthermia cancer therapy: From fundamental principles to advanced applications. J Control Release 235: 205-221, 2016.

9. Amer MH: Gene therapy for cancer: Present status and future perspective. Mol Cell Ther 2: 27, 2014. 

10. Tolmasky ME: Plasmids. Reference Module in Life Sciences: Elsevier, 2017. 

11. Fang CY, Tsai YD, Lin MC, Wang M, Chen PL, Chao CN, Huang YL, Chang D and Shen CH: Inhibition of human bladder cancer growth by a suicide gene delivered by JC polyomavirus virus-like particles in a mouse model. J Urol 193: 2100-2106, 2015. 

12. Kim HA, Nam K, Lee M and Kim SW: Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. J Control Release 171: 1-10, 2013. 

13. Lazarus GG and Singh M: In vitro cytotoxic activity and trans fection efficiency of polyethyleneimine functionalized gold nanoparticles. Colloids Surf B Biointerfaces 145: 906-911, 2016.

14. Pr uitt KD, Brown GR, Hiatt SM, Thibaud-Nissen F, Astashyn A, Ermolaeva O, Farrell CM, Hart J, Landrum MJ, McGarvey KM, et al: RefSeq: An update on mammalian reference sequences. Nucleic Acids Res 42 (Database Issue): D756-D763, 2014. 

15. Luo C, Miao L, Zhao Y, Musetti S, Wang Y, Shi K and Huang L: A novel cationic lipid with intrinsic antitumor activity to facili tate gene therapy of TRAIL DNA. Biomaterials 102: 239-248, 2016. 

16. Inoue N, Watanabe M, Ishido N, Kodu A, Maruoka H, Katsumata Y, Hidaka Y and Iwatani Y: Involvement of genes encoding apoptosis regulatory factors (FAS, FASL, TRAIL, BCL2, TNFR1 and TNFR2) in the pathogenesis of autoimmune thyroid diseases. Hum Immunol 77: 944-951, 2016. 

17. Zhan C, Li C, Wei X, Lu W and Lu W: Toxins and derivatives in molecular pharmaceutics: Drug delivery and targeted therapy.

Adv Drug Deliv Rev 90: 101-118, 2015.

18. Glinka EM: Eukaryotic expression vectors bearing genes

encoding cytotoxic proteins for cancer gene therapy. Plasmid 68: 69-85, 2012. 19. Walsh MJ, Dodd JE and Hautbergue GM: Ribosome-inactivating

proteins: Potent poisons and molecular tools. Virulence 15: 774-784, 2013.

20. Glinka EM: Eukaryotic expression vectors containing genes

encoding plant proteins for killing of cancer cells. Cancer Epidemiol 37: 1014-1019, 2013.

21. Malekshah OM, Chen X, Nomani A, Sarkar S and Hatefi A: Enzyme/prodrug systems for cancer gene therapy. Curr Pharmacol Rep 2: 299-308, 2016. 22. Duarte S, Carle G, Faneca H, de Lima MC and Pierrefite‑Carle V: Suicide gene therapy in cancer: Where do we stand now? Cancer Lett 324: 160-170, 2012.

23. Karjoo Z, Chen X and Hatefi A: Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev 99: 113-128, 2016.

24. Abu Lila AS, Uehara Y, Ishida T and Kiwada H: Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid

delivery. J Pharm Sci 103: 557-566, 2014.

25. Badrinath N, Heo J and Yoo SY: Viruses as nanomedicine for cancer. Int J Nanomedicine 11: 4835-4847, 2016.

26. Dizaj SM, Jafari S and Khosroushahi AY: A sight on the current

nanoparticle-based gene delivery vectors. Nanoscale Res Lett 9: 252, 2014.

27. Crespo-Barreda A, Encabo-Berzosa MM, González-Pastor R, Ortíz-Teba P, Iglesias M, Serrano JL and Duque-Martin P: Chapter 11-viral and nonviral vectors for in vivo and ex vivo gene therapies A2-laurence, Jeffrey. Trans Regenerative Med Clinic. Boston, Academic Press, pp155-177, 2016.

28. Zou W, Liu C, Chen Z and Zhang N: Preparation and charac terization of cationic PLA-PEG nanoparticles for delivery of plasmid DNA. Nanoscale Res Lett 4: 982-992, 2009.

29. Raju D, Vishwakarma RK, Khan BM, Mehta UJ and Ahmad A: Biological synthesis of cationic gold nanoparticles and binding of plasmid DNA. Mater Lett 129: 159-161, 2014.

30. Anselmo AC and Mitragotri S: Nanoparticles in the clinic.

Bioeng Trans Med 1: 10-29, 2016.

31. Gebremedhin S, Singh A, Koons S, Bernt W, Konopka K and

Duzgunes N: Gene delivery to carcinoma cells via novel non-viral vectors: Nanoparticle tracking analysis and suicide gene therapy. Eur J Pharm Sci 60: 72-79, 2014.

32. Gao S, Tian H, Xing Z, Zhang D, Guo Y, Guo Z, Zhu X and Chen X: A non-viral suicide gene delivery system traversing the blood brain barrier for non-invasive glioma targeting treatment.

J Control Release 243: 357-369, 2016.

33. Eslaminejad T, Nematollahi-Mahani SN and Ansari M: Synthesis, characterization and cytotoxicity of the plasmid EGFP-p53 loaded on pullulan-spermine magnetic nanoparticles. J Magn Magn Mater 402: 34-43, 2016.

34. McBride JW, Massey AS, McCaffrey J, McCrudden CM, Coulter JA, Dunne NJ, Robson T and McCarthy HO: Development

of TMTP-1 targeted designer biopolymers for gene delivery to

prostate cancer. Int J Pharm 500: 144-153, 2016.

35. Wang K, Kievit FM and Zhang M: Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies. Pharmacol

Res 114: 56-66, 2016.

36. Islam MA, Park TE, Singh B, Maharjan S, Firdous J, Cho MH, Kang SK, Yun CH, Choi YJ and Cho CS: Major degradable poly cations as carriers for DNA and siRNA. J Control Release 193: 74-89, 2014. 37. Pérez-Herrero E and Fernández-Medarde A: Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemo therapy. Eur J Pharm Biopharm 93: 52-79, 2015.

38. Bishop CJ, Majewski RL, Guiriba TR, Wilson DR, Bhise NS, Quiñones‑Hinojosa A and Green JJ: Quantification of cellular and nuclear uptake rates of polymeric gene delivery nanopar ticles and DNA plasmids via flow cytometry. Acta Biomater 37: 120-130, 2016.

39. Guo J, O'Driscoll CM, Holmes JD and Rahme K: Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells. Int J Pharm 509: 16-27, 2016.

40. Masood F: Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C Mater Biol Appl 60: 569-578, 2016.

41. Carrillo C, Suñé JM, Pérez-Lozano P, García-Montoya E, Sarrate R, Fàbregas A, Miñarro M and Ticó JR: Chitosan nanopar ticles as non-viral gene delivery systems: Determination of loading efficiency. Biomed Pharmacother 68: 775‑783, 2014.

42. Bor G, Mytych J, Zebrowski J, Wnuk M and Şanli‑Mohamed G: Cytotoxic and cytostatic side effects of chitosan nanoparticles as a non-viral gene carrier. Int J Pharm 513: 431-437, 2016.

43. Zhou J, Deng W, Wang Y, Cao X, Chen J, Wang Q, Xu W, Du P, Yu Q, Chen J, et al: Cationic carbon quantum dots derived from alginate for gene delivery: One-step synthesis and cellular uptake. Acta Biomater 42: 209-219, 2016. 

44. Tirkey B, Bhushan B, Uday Kumar S and Gopinath P: Prodrug encapsulated albumin nanoparticles as an alternative approach to manifest anti-proliferative effects of suicide gene therapy. Mater Sci Eng C Mater Biol Appl 73: 507-515, 2017. 

45. Shi S, Shi K, Tan L, Qu Y, Shen G, Chu B, Zhang S, Su X, Li X, Wei Y and Qian Z: The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxoru bicin. Biomaterials 35: 4536-4547, 2014. 

46. Gaspar VM, Baril P, Costa EC, de Melo-Diogo D, Foucher F, Queiroz JA, Sousa F, Pichon C and Correia IJ: Bioreducible poly (2-ethyl-2-oxazoline)-PLA-PEI-SS triblock copolymer micelles for co-delivery of DNA minicircles and Doxorubicin. J Control Release 213: 175-191, 2015. 

47. Peng SF, Hsu HK, Lin CC, Cheng YM and Hsu KH: Novel PEI/Poly-γ‑Gutamic Acid Nanoparticles for high efficient siRNA and Plasmid DNA Co-Delivery. Molecules 22: pii:E86, 2017.

48. Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, et al: Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemo therapy-resistant ovarian cancer cells. Mol Cancer Ther 16: 323-333, 2017. 

49. Frede A, Neuhaus B, Klopfleisch R, Walker C, Buer J, Müller W, Epple M and Westendorf AM: Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles amelio rates intestinal inflammation in vivo. J Control Release 222: 86-96, 2016. 

50. Ohta T, Hashida Y, Higuchi Y, Yamashita F and Hashida M: In vitro cellular gene delivery employing a novel composite material of single-walled carbon nanotubes associated with designed peptides with pegylation. J Pharm Sci 106: 792-802, 2017.

51. Shekhar S, Roy A, Hong D and Kumta PN: Nanostructured silicate substituted calcium phosphate (NanoSiCaPs) nanoparticles‑efficient calcium phosphate based non‑viral gene delivery systems. Mater Sci Eng C Mater Biol Appl 69: 486-495, 2016. 

52. Li Y, Hei M, Xu Y, Qian X and Zhu W: Ammonium salt modified mesoporous silica nanoparticles for dual intracellular-responsive gene delivery. Int J Pharm 511: 689-702, 2016. 

53. El-Sherbiny IM, Elbaz NM, Sedki M, Elgammal A and Yacoub MH: Magnetic nanoparticles-based drug and gene delivery systems for the treatment of pulmonary diseases. Nanomedicine (Lond) 12: 387-402, 2017. 

54. Sun J, Shi Z, Jia S and Zhang P: The force analysis for super paramagnetic nanoparticles-based gene delivery in an oscillating magnetic field. J Magn Magn Mater 427: 85‑89, 2017. 

55. Sun T, Zhang YS, Pang B, Hyun DC, Yang M and Xia Y: Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl 53: 12320-12344, 2014. 

56. Xu X, Ho W, Zhang X, Bertrand N and Farokhzad O: Cancer nanomedicine: From targeted delivery to combination therapy. Trends Mol Med 21: 223-232, 2015. 

57. Yang Y and Yu C: Advances in silica based nanoparticles for targeted cancer therapy. Nanomedicine 12: 317-332, 2016. 

58. Suk JS, Xu Q, Kim N, Hanes J and Ensign LM: PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99: 28-51, 2016. 

59. Casettari L, Vllasaliu D, Castagnino E, Stolnik S, Howdle S and Illum L: PEGylated chitosan derivatives: Synthesis, characterizations and pharmaceutical applications. Prog Polym Sci 37: 659-685, 2012. 

60. Palacio J, Agudelo NA and Lopez BL: PEGylation of PLA

nanoparticles to improve mucus-penetration and colloidal stability for oral delivery systems. Curr Opin Chem Eng 11: 14-19, 2016.

61. Kim J, Kang Y, Tzeng SY and Green JJ: Synthesis and applica tion of poly (ethylene glycol)-co-poly (β-amino ester) copolymers for small cell lung cancer gene therapy. Acta Biomaterialia 41: 293-301, 2016.

62. Ahmed S, Sami A and Xiang J: HER2-directed therapy: Current treatment options for HER2-positive breast cancer. Breast Cancer 22: 101-116, 2015.

63. Zhu L, Staley C, Kooby D, El-Rays B, Mao H and Yang L: Current status of biomarker and targeted nanoparticle develop ment: The precision oncology approach for pancreatic cancer therapy. Cancer Lett 388: 139-148, 2017.

64. Grunewald T and Ledermann JA: Targeted Therapies for Ovarian

Cancer. Best Pract Res Clin Obstet Gynaecol 14: 139-152, 2017.

65. McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, Ma S, Kaplan J, Barbaglio F, Gordon LI, et al: Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. Oncotarget 8:

11219-11227, 2017. 66. Liu J, Zhao D, He W, Zhang H, Li Z and Luan Y: Nanoassemblies

from amphiphilic cytarabine prodrug for leukemia targeted therapy. J Colloid Interface Sci 487: 239-249, 2017.

67. Pillai MR, Nanabala R, Joy A, Sasikumar A and Knapp FF:

Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol 43: 692-720, 2016. 68. Xie T, Dong B, Yan Y, Hu G and Xu Y: Association between

MMP-2 expression and prostate cancer: A meta-analysis. Biomed Rep 4: 241-245, 2016.

69. Tarokh Z, Naderi-Manesh H and Nazari M: Towards prostate

cancer gene therapy: Development of a chlorotoxin-targeted nanovector for toxic (melittin) gene delivery. Eur J Pharm Sci 99: 209-218, 2017. 70. Sun L, Wu Q, Peng F, Liu L and Gong C: Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy. Colloids Surf B Biointerfaces 135: 56-72, 2015.

71. Christian CG, Carlos MP, Alejandro MM, Imelda OA, Oscar ZT,

Adriana ME and Perla GC: Development of antibody-coated magnetite nanoparticles for biomarker immobilization. Journal of Nanomaterials 2014: 7, 2014.

72. Thorek DL, Elias DR and Tsourkas A: Comparative analysis of

nanoparticle-antibody conjugations: Carbodiimide versus click

chemistry. Mol Imaging 8: 221-229, 2009.

73. Crivianu-Gaita V and Thompson M: Aptamers, antibody scFv, and antibody Fab' fragments: An overview and comparison of three of the most versatile biosensor biorecognition elements. Biosens Bioelectron 85: 32-45, 2016.

74. Kim J, Wilson DR, Zamboni CG and Green JJ: Targeted poly meric nanoparticles for cancer gene therapy. J Drug Target 23: 627-641, 2015.

75. Cheraghi R, Nazari M, Alipour M, Majidi A and Hosseinkhani S:

Development of a targeted anti-HER2 scFv chimeric peptide for gene delivery into HER2-positive breast cancer cells. Int J Pharm 515: 632-643, 2016.

76. Cai Z, Chattopadhyay N, Yang K, Kwon YL, Yook S, Pignol JP

and Reilly RM: 111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after

intratumoral injection. Nucl Med Biol 43: 818-826, 2016.

77. Yin XB, Wu LQ, Fu HQ, Huang MW, Wang K, Zhou F, Yu X and Wang KY: Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: In vitro and in vivo studies.

Asian Pac J Trop Med 7: 337-343, 2014.

78. Xiangbao Y, Linquan W, Mingwen H, Fan Z, Kai W, Xin Y, Kaiyang W and Huaqun F: Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with

potent and selective anti-hepatocellular carcinoma activity. Biomed Pharmacother 68: 597-602, 2014.